These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 23427817)
1. Prolonged gene expression in muscle is achieved without active immune tolerance using microrRNA 142.3p-regulated rAAV gene transfer. Boisgerault F; Gross DA; Ferrand M; Poupiot J; Darocha S; Richard I; Galy A Hum Gene Ther; 2013 Apr; 24(4):393-405. PubMed ID: 23427817 [TBL] [Abstract][Full Text] [Related]
2. A dystrophic muscle broadens the contribution and activation of immune cells reacting to rAAV gene transfer. Ferrand M; Galy A; Boisgerault F Gene Ther; 2014 Sep; 21(9):828-39. PubMed ID: 25030611 [TBL] [Abstract][Full Text] [Related]
3. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. Cordier L; Gao GP; Hack AA; McNally EM; Wilson JM; Chirmule N; Sweeney HL Hum Gene Ther; 2001 Jan; 12(2):205-15. PubMed ID: 11177557 [TBL] [Abstract][Full Text] [Related]
5. Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products. Yuasa K; Yoshimura M; Urasawa N; Ohshima S; Howell JM; Nakamura A; Hijikata T; Miyagoe-Suzuki Y; Takeda S Gene Ther; 2007 Sep; 14(17):1249-60. PubMed ID: 17581597 [TBL] [Abstract][Full Text] [Related]
6. Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity. Xiao Y; Muhuri M; Li S; Qin W; Xu G; Luo L; Li J; Letizia AJ; Wang SK; Chan YK; Wang C; Fuchs SP; Wang D; Su Q; Nahid MA; Church GM; Farzan M; Yang L; Wei Y; Desrosiers RC; Mueller C; Tai PW; Gao G JCI Insight; 2019 May; 5(13):. PubMed ID: 31112525 [TBL] [Abstract][Full Text] [Related]
10. Muscle as a target for supplementary factor IX gene transfer. Hoffman BE; Dobrzynski E; Wang L; Hirao L; Mingozzi F; Cao O; Herzog RW Hum Gene Ther; 2007 Jul; 18(7):603-13. PubMed ID: 17594244 [TBL] [Abstract][Full Text] [Related]
11. rAAV vector-mediated sarcogylcan gene transfer in a hamster model for limb girdle muscular dystrophy. Li J; Dressman D; Tsao YP; Sakamoto A; Hoffman EP; Xiao X Gene Ther; 1999 Jan; 6(1):74-82. PubMed ID: 10341878 [TBL] [Abstract][Full Text] [Related]
12. Mir-142-3p target sequences reduce transgene-directed immunogenicity following intramuscular adeno-associated virus 1 vector-mediated gene delivery. Majowicz A; Maczuga P; Kwikkers KL; van der Marel S; van Logtenstein R; Petry H; van Deventer SJ; Konstantinova P; Ferreira V J Gene Med; 2013; 15(6-7):219-32. PubMed ID: 23658149 [TBL] [Abstract][Full Text] [Related]
13. Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice. Lochmüller H; Petrof BJ; Pari G; Larochelle N; Dodelet V; Wang Q; Allen C; Prescott S; Massie B; Nalbantoglu J; Karpati G Gene Ther; 1996 Aug; 3(8):706-16. PubMed ID: 8854096 [TBL] [Abstract][Full Text] [Related]
14. Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D. Rodino-Klapac LR; Lee JS; Mulligan RC; Clark KR; Mendell JR Neurology; 2008 Jul; 71(4):240-7. PubMed ID: 18525034 [TBL] [Abstract][Full Text] [Related]
15. Impairment of force generation after adenovirus-mediated gene transfer to muscle is alleviated by adenoviral gene inactivation and host CD8+ T cell deficiency. Petrof BJ; Lochmüller H; Massie B; Yang L; Macmillan C; Zhao JE; Nalbantoglu J; Karpati G Hum Gene Ther; 1996 Oct; 7(15):1813-26. PubMed ID: 8894673 [TBL] [Abstract][Full Text] [Related]